In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1, 6, 16, and 20, and add new claims 22-26 as follows:

1. (currently amended) A compound of formula (I)



I

wherein

R^1 ~~and R^2 are independently selected from phenyl, thienyl and pyridyl~~ is phenyl or thienyl, each of which is independently optionally substituted with one, two or three Z groups;

R^2 is selected from phenyl, thienyl and pyridyl, each of which is independently optionally substituted with one, two or three Z groups;

Z is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and –CONHNR^{a}R^b, wherein R^a and R^b are R^4 and R^5, respectively; and

X is CO or SO_2 ;

Y is absent ~~or NH, optionally substituted with a C_{1-3}alkyl group~~;

R^4 and R^5 are independently selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted with one

or more C_{1-3}alkyl groups;

~~an optionally substituted~~ a non-aromatic C_{3-15}carbocyclic group;

~~a (C_{3-12}cycloalkyl)C_{1-3}alkyl group;~~

a $-(CH_2)_r$(phenyl $)_s$ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three ~~Z groups~~ groups selected from C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, or hydroxy ~~or benzyl~~;

1-adamantylmethyl; and

a $-(CH_2)_t$Het group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted with one or more C_{1-3}alkyl groups and wherein Het is an aromatic heterocycle optionally substituted with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group and halo;

or R^4 is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxy or benzyl;

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

with the proviso that when R^6 is methyl, then the group X-Y-NR^4R^5 is not $CONHC_6H_{13}$, $CONHC_{12}H_{25}$, $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$,  or  ;

and with the further proviso that when R^1 and R^2 are independently phenyl, then Z is not an ortho methyl group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

2. (previously presented) A compound according to claim 1, wherein R^1 is phenyl optionally substituted in the 2 or 4 position with halo or C_{1-3}alkoxy.

3. (previously presented) A compound according to claim 1, wherein R^2 is phenyl, optionally substituted in the 2 or 4 position with halo or C_{1-3}alkoxy.

4. (previously presented) A compound according to claim 1, wherein X-Y-NR^4R^5 is CONHPh or CONH(1-piperidyl).

5. (previously presented) A compound according to claim 1, wherein R^6 is methyl.

6. (currently amended) A compound according to claim 1 of the general formula (II)



II

wherein

m is 0, 1, 2 or 3

each R^7 is independently selected from a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, and halo;

n is 0, 1, 2 or 3;

each R^8 is independently selected from a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, and halo;

R^9 is 1-piperidinyl, ~~1 piperidinylamino~~ and aniline, wherein the phenyl ring is optionally substituted with one or more of the following: a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, or trifluoromethoxy~~, or halo~~; and

R^{10} is selected from a C_{1-6}alkyl, C_{1-6}alkoxy, and a C_{1-6}alkylamino group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof;

with the proviso that the compound is not 1-{[1-(4-chlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine or 1-{[1-(2,4-dichlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine.

7. (previously presented) A compound according to claim 6, wherein m is 2 and each R^7, if present, is located in the 2 or 4 position of the phenyl ring.

8. (previously presented) A compound according to claim 6, wherein n is 2 and each R^8, if present, is located in the 2 or 4 position of the phenyl ring.

9. (previously presented) A compound according to claim 6, wherein R^9 is 1-piperidinyl.

10. (previously presented) A compound according to claim 6, wherein R^9 is 1-piperidinylamino.

11. (previously presented) A compound according to claim 6, wherein R^{10} is methyl.

12. (previously presented) A compound selected from:

2-methyl-*N*,1,5-triphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-*N*,5-diphenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-2-methyl-*N*,1-diphenyl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-phenyl-1*H*-pyrrole-3-carboxamide;

2-methyl-1,5-diphenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-methoxyphenyl)-2-methyl-5-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-{[5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-*N*-piperidin-1-yl-1*H*-pyrrole-3-carboxamide;

1-[(2-methyl-1,5-diphenyl-1*H*-pyrrol-3-yl)carbonyl]piperidine;

1-{[1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[5-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

1-{[1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine; and

1-{[5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine;

and where applicable, optical isomers, tautomers, stereoisomers and racemates thereof as well as pharmaceutically acceptable salts and solvates thereof.

13. (cancelled).

14. (previously presented) A pharmaceutical composition comprising a compound of any one of claims 1 to 12 and a pharmaceutically acceptable adjuvant, diluent or carrier.

15. (cancelled).

16. (currently amended) A method of treating a condition selected from obesity, psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, neurological disorders, dementia, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems, and extended abuse, addiction and/or relapse indications, in a mammal, comprising administering a pharmacologically effective amount of a compound of formula (I)



I

wherein

R^1 ~~and R^2 are independently selected from phenyl, thienyl and pyridyl~~ is phenyl or thienyl, each of which is independently optionally substituted with one, two or three Z groups;

R^2 is selected from phenyl, thienyl and pyridyl, each of which is independently optionally substituted with one, two or three Z groups;

Z is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

X is CO or SO_2 ;

Y is absent ~~or NH, optionally substituted with a C_{1-3}alkyl group~~;

R^4 and R^5 are independently selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted with one or more C_{1-3}alkyl groups;

~~an optionally substituted~~ a non-aromatic C_{3-15}carbocyclic group;

~~a (C_{3-12}cycloalkyl)C_{1-3}alkyl group;~~

a $-(CH_2)_r$(phenyl $)_s$ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three ~~Z groups~~ groups selected from C_{1-3}alkyl group, a

C_{1-3}alkoxy group, hydroxy, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, or hydroxy ~~or benzyl~~;

1-adamantylmethyl; and

a $-(CH_2)_t$Het group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted with one or more C_{1-3}alkyl groups and wherein Het is an aromatic heterocycle optionally substituted with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group and halo;

or R^4 is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxy or benzyl;

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively;

with the proviso that when R^6 is methyl, then the group $X\text{-}Y\text{-}NR^4R^5$ is not $CONHC_6H_{13}$, $CONHC_{12}H_{25}$, $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$,  or



;

and with the further proviso that when R^1 and R^2 are independently phenyl, then Z is not an ortho methyl group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof;

[[and]] to a patient in need thereof.

17. (cancelled).

18. (previously presented) A process for the preparation of a compound of claim 1 in which X is CO, comprising reacting a compound of formula III



III

in which R^1, R^2, R^3, and R^6 are as previously defined and wherein L is hydroxy or halo, with an amine of formula IV

$$R^4R^5YNH_2 \qquad IV$$

in which R^4 and R^5 are as previously defined, in an inert solvent and optionally in the presence of a catalyst or optionally in the presence of a base at a temperature in the range of -25°C to 150°C, and, when L is hydroxyl, optionally in the presence of a coupling agent.

19. (previously presented) A compound of formula III



III

wherein R^1, R^2, R^3, and R^6 are as defined in claim 1 and L is hydroxy or halo.

20. (currently amended) A compound selected from:

~~Ethyl 2-methyl-1,5-diphenyl-1*H*-pyrrole-3-carboxylate,~~

Ethyl 1-(4-chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,

Ethyl 1-(4-methoxyphenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylate,

Ethyl 5-(2,4-dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,

Ethyl 1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,

Ethyl 5-(2,4-dichlorophenyl)- 1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,

Ethyl 5-(2,4-dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylate,

Ethyl 1-(4-chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,

Ethyl 5-(2,4-dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylate,

~~2-Methyl-1,5-diphenyl-1*H*-pyrrole-3-carboxylic acid,~~

1-(4-Chlorophenyl)-2-methyl-5-phenyl-1*H*-pyrrole-3-carboxylic acid,

5-(2,4-Dichlorophenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,

1-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,

5-(2,4-Dichlorophenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid,

5-(2,4-Dimethoxyphenyl)-2-methyl-1-phenyl-1*H*-pyrrole-3-carboxylic acid,

1-(4-Chlorophenyl)-5-(2,4-dimethoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid, and

5-(2,4-Dimethoxyphenyl)-1-(4-methoxyphenyl)-2-methyl-1*H*-pyrrole-3-carboxylic acid.

21. (previously presented) The composition according to claim 14, comprising an additional agent useful in the treatment of hypertension, hyperlipidaemias, dyslipidaemias, diabetes or atherosclerosis.

22. (new) A compound of formula (I)



I

wherein

R^1 is phenyl or thienyl, each of which is independently optionally substituted with one, two or three Z groups;

R^2 is selected from phenyl, thienyl and pyridyl, each of which is independently optionally substituted with one, two or three groups selected from C_{1-3}alkyl group, hydroxy, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

Z is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

X is CO or SO_2 ;

Y is absent or NH, optionally substituted with a C_{1-3}alkyl group;

R^4 and R^5 are independently selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted with one or more C_{1-3}alkyl groups;

a non-aromatic C_{3-15}carbocyclic group;

a $–(CH_2)_r$(phenyl $)_s$ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three groups selected from C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, or hydroxy;

1-adamantylmethyl; and

a $–(CH_2)_t$Het group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted with one or more C_{1-3}alkyl groups and wherein Het is an aromatic heterocycle optionally substituted with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group and halo;

or R^4 is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxyl, or benzyl;

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a

hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and –$CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

with the proviso that when R^6 is methyl, then the group X-Y-NR^4R^5 is not $CONHC_6H_{13}$, $CONHC_{12}H_{25}$, $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$,  or  ;

and with the further proviso that when R^1 and R^2 are independently phenyl, then Z is not an ortho methyl group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

23. (new) A compound according to claim 22 of the general formula (II)



II

wherein

m is 0, 1, 2 or 3

each R^7 is independently selected from a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy group, difluoromethoxy, trifluoromethoxy, and halo;

n is 0, 1, 2 or 3;

each R^8 is independently selected from a C_{1-6}alkyl group, trifluoromethyl, difluoromethoxy, and trifluoromethoxy;

R^9 is 1-piperidinyl, 1-piperidinylamino and aniline, wherein the phenyl ring is optionally substituted with one or more of the following: a C_{1-6}alkyl group, trifluoromethyl, a C_{1-6}alkoxy

group, difluoromethoxy, or trifluoromethoxy; and

R^{10} is selected from a C_{1-6}alkyl, C_{1-6}alkoxy, and a C_{1-6}alkylamino group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof;

with the proviso that the compound is not 1-{[1-(4-chlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine or 1-{[1-(2,4-dichlorophenyl)-5-phenyl-2-methyl-1*H*-pyrrol-3-yl]carbonyl}piperidine.

24. (new) A method of treating a condition selected from obesity, psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, neurological disorders, dementia, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems, and extended abuse, addiction and/or relapse indications, in a mammal, comprising administering a pharmacologically effective amount of a compound of formula (I)



I

wherein:

R^1 is phenyl or thienyl, each of which is independently optionally substituted with one, two or three Z groups;

R^2 is selected from phenyl, thienyl and pyridyl, each of which is independently optionally substituted with one, two or three groups selected from C_{1-3}alkyl group, hydroxy, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl

carbamoyl, sulphamoyl and acetyl;

Z is selected from a C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

R^3 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, an aminoC_{1-3}alkyl group, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

X is CO or SO_2 ;

Y is absent or NH, optionally substituted with a C_{1-3}alkyl group;

R^4 and R^5 are independently selected from:

a C_{1-6}alkyl group;

an (amino)C_{1-4}alkyl– group in which the amino is optionally substituted with one or more C_{1-3}alkyl groups;

a non-aromatic C_{3-15}carbocyclic group;

a $-(CH_2)_r$(phenyl $)_s$ group, wherein r is 0, 1, 2, 3 or 4, and wherein s is 1 when r is 0, otherwise s is 1 or 2, and wherein the phenyl groups are optionally independently substituted with one, two or three groups selected from C_{1-3}alkyl group, a C_{1-3}alkoxy group, hydroxy, trifluoromethylthio, difluoromethoxy, trifluoromethoxy, trifluoromethylsulphonyl, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkyl carbamoyl, sulphamoyl and acetyl;

naphthyl;

anthracenyl;

a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen, wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, or hydroxy;

1-adamantylmethyl; and

a $-(CH_2)_tHet$ group, wherein t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted with one or more C_{1-3}alkyl groups and wherein Het is an aromatic heterocycle optionally substituted with one, two or three groups selected from a C_{1-5}alkyl group, a C_{1-5}alkoxy group and halo;

or R^4 is H and R^5 is as defined above;

or R^4 and R^5 taken together with the nitrogen atom to which they are attached form a saturated 5- to 8-membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; wherein the heterocyclic group is optionally substituted with one or more C_{1-3}alkyl groups, hydroxyl, or benzyl;

R^6 is selected from H, a C_{1-3}alkyl group, a C_{1-3}alkoxymethyl group, trifluoromethyl, a hydroxyC_{1-3}alkyl group, C_{1-3}alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3}alkylcarbamoyl, acetyl, and $-CONHNR^aR^b$, wherein R^a and R^b are R^4 and R^5, respectively; and

with the proviso that when R^6 is methyl, then the group $X\text{-}Y\text{-}NR^4R^5$ is not $CONHC_6H_{13}$,  $CONHC_{12}H_{25}$, $CONH_2$, $CONHCH_3$, $CON(CH_3)_2$, or  ;

and with the further proviso that when R^1 and R^2 are independently phenyl, then Z is not an ortho methyl group;

or a pharmaceutically acceptable salt, prodrug or solvate thereof

25. (new) A process for the preparation of a compound of claim 22 in which X is CO, comprising reacting a compound of formula III



III

in which R^1, R^2, R^3, and R^6 are as defined in claim 22 and wherein L is hydroxy or halo, with an amine of formula IV

$$R^4R^5YNH_2 \qquad IV$$

in which R^4 and R^5 are as defined in claim 22, in an inert solvent and optionally in the presence of a catalyst or optionally in the presence of a base at a temperature in the range of -25°C to 150°C, and, when L is hydroxyl, optionally in the presence of a coupling agent.

26. (new) A compound of formula III



III

wherein R^1, R^2, R^3, and R^6 are as defined in claim 22 and L is hydroxy or halo.